

PAR/CS/NSE/2021-22/17

Date: 10/06/2021

To,
The Manager
Listing department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400 051
Maharashtra


Subject: Outcome of the Board Meeting held on Thursday, 10th day of June, 2021 in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015

Ref.: Symbol- PAR (NSE Emerge), ISIN: INE04LG01015

Dear Sir/Madam,

The meeting of Board of Directors of the Company held on **Thursday, 10th day of June, 2021 at 4:15 PM** through Video Conferencing ("VC") mode inter alia transacted the following business:

Item No.	Outcomes
1.	The board considered, decided and approved migration of Listing and Trading of the Equity Shares of the Company from National Stock Exchange of India Limited (NSE) SME Platform (i.e. Emerge) to Main Board of National Stock Exchange of India Limited (NSE) subject to necessary approvals including approval of Members of the Company by way of Postal Ballot.
2.	The board has approved cut-off date 11 th Day of June, 2021 for determining Shareholders entitled to vote by Postal Ballot & E-voting and the calendar of event determining various dates for postal ballot process which will be available to the shareholders with due course of time.
3.	The Board has approved Notice of postal ballot incorporating proposed Resolution(s) and explanatory statement thereto, e-voting & ballot form, instruction & other particulars as required and the Board has authorised Company Secretary of the company to conduct postal ballot process and sign and send the Notice of Postal Ballot along with other documents and proceed for the whole postal ballot process with due course of time.
4.	The Board decided to appoint CS Dip G. Patel, proprietor of DG Patel & Associates, Company Secretaries (FCS: 10533; COP No. 13774) as a Scrutinizer to scrutinize the votes cast by the members through remote e-voting for postal ballot process in a fair and transparent manner.
5.	The Board has decided to appoint Link Intime India Private Limited ("RTA") an Agency for providing facility of e-voting facility for the postal ballot process.
6.	The Board considered and approved the drafts of advertisements to be published in newspapers regarding Postal Ballot Notice, e-voting information and other related disclosures. The Board decided to publish the said advertisements in the Economic Times & Navgujarat Samay.
7.	The board received, considered and approved the audited financial results for half year and year ended on 31 st March, 2021 along with statement of assets and liabilities, statement of profit & loss and cash flow statement together with Auditors Report with unmodified opinion thereon . The said Audited Financial Results along with Auditors' Report, Declaration pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended time to time, and Certificate of correctness of Financial statement pursuant to Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended time to time are attached herewith respectively as Annexure-1,2 & 3. The above audited financial results were reviewed by Audit Committee at its meeting.
8.	The Board received, considered and approved Annual Audited financial statement with Audit Report for F.Y. 2020-21 ended on 31 st March, 2021.



9.	The Board received and considered Secretarial Audit Report on the Secretarial records of the Company for the year ended 31 st March, 2021 as placed before the Board and initialled by the Chairman for the purpose of identification and approved and the same is recommended to the members for adoption in forthcoming ensuring Annual General Meeting.
10.	The Board received, considered and approved Internal Audit Report based on internal audit conducted by M/s. SIDDHPURA & CO, Chartered Accountants for F.Y. 2020-21.
11.	The Board received, considered and approved Human Resource Annual Report as presented for the F.Y. 2020-21 by the HR head of the Company to the management and recommended some improvement of HR Department efficiency for the next year.
12.	The Board took note of Actuarial valuation report as per AS 15 under the defined benefit scheme of Gratuity Benefits for the financial year ended 31 st March, 2021 received from Kapdiya Actuaries & Consultant.
13.	The Board considered and approved the appointment of M/s DG Patel & Associates, Company Secretaries (FCS No. 10533, C.P. No.: 13774) as Secretarial Auditors of the Company pursuant to Section 204 of the Companies Act, 2013 for conducting secretarial audit for the F.Y. 2021-22. The Profile of Secretarial Auditors is attached herewith as Annexure-4
14.	The Board authorized to M/s DG Patel & Associates, Company Secretaries (FCS No. 10533, C.P. No.: 13774) to issue Annual Secretarial Compliance Report for the F.Y. 2020-21 before 30 th June, 2021, in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/27/2019 dated February 08, 2019.
15.	The Board reviewed all policies of the Company.
16.	Board reviewed terms and Conditions of appointment of Independent Directors
17.	Board reviewed the code of conduct of the company.
With the permission of the Chairman of the Company, following other matter was considered	
18.	The Board took note of starting of new product line facility within the existing factory unit available at Bhavnagar, Gujarat, which is now operating in full fledge within the current available product portfolio of the Company, which will increase the production capacity of the Company.

Further, in continuation of our intimation dated 30th March, 2021 and pursuant to Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and amendment made time to time till date and according to Company's Code of Conduct to Regulate, Monitor and Report Trading by Insiders, the trading window for trading in securities of the Company will remain closed till the expiry of 48 hours after declaration of postal ballot voting result by the Company.

The Board Meeting was commenced at 4:15 PM and concluded at 5:05 PM.

Kindly take on the record and acknowledge the receipt.


Yours Faithfully,

For PAR DRUGS AND CHEMICALS LIMITED



(Sanket B. Trivedi)

Company Secretary & Compliance Officer



Annexure:

1. Financial statements include statement of assets and liabilities, statement of profit & loss and cash flow statement together with Auditor's Report
2. Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015
3. Certificate of Correctness of financial Statement
4. Profile of Secretarial Auditor



INDEPENDENT AUDITOR'S REPORT

(Auditor's Report on Standalone Financial Results pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015)

TO
THE BOARD OF DIRECTORS OF
PAR DRUGS AND CHEMICALS LIMITED

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying standalone half yearly financial results of **PAR DRUGS AND CHEMICALS LIMITED** (the company) for the **half year ended 31st March, 2021** and the year to date results for the period from **1st April, 2020 to 31st March, 2021**, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:


- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the **net profit** and other comprehensive income and other financial information for the half year ended **31st March, 2021** as well as the year to date results for the period from **1st April, 2020 to 31st March, 2021**

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

These half yearly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net



Bhavnagar: 320, Imperial Arc, Opp University Gate, Waghawadi Road, Bhavnagar-364001

Surat: Office No.-1, Tulsi Arcade, Opp. Gabani Hospital, Station Road, Surat-395003

Cell : +91 – 9898027172 / Phone No : 0278-2570300

E-Mail : vipuldhamsania@gmail.com



profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.


The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.



Bhavnagar: 320, Imperial Arc, Opp University Gate, Waghawadi Road, Bhavnagar-364001

Surat: Office No.-1, Tulsi Arcade, Opp. Gabani Hospital, Station Road, Surat-395003

Cell : +91 – 9898027172 / Phone No : 0278-2570300

E-Mail : vipuldhamsania@gmail.com




- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

V DHAMSANIA & ASSOCIATES
(Firm Regn No. – 132499W)
CHARTERED ACCOUNTANTS

VIPUL V DHAMSANIA (Partner)
M.No.140836
Bhavnagar, 10th June, 2021
UDIN - 21140836AAAAHF3007



PAR DRUGS AND CHEMICALS LIMITED

(CIN : L24117GJ1999PLC035512)

Registered Office : 815, Nilamber Triumph, Gotri Vasna Road, Vadodara (Gujarat)

Audited Financial Results for the Half Year Ended 31st March, 2021

Statement Of Assets And Liabilities

Rs. In Lakhs

Particulars		AS AT 31.03.2021	AS AT 30.09.2020	AS AT 31.03.2020	AS AT 30.09.2019
		Audited	Unaudited	Audited	Unaudited
I. EQUITY AND LIABILITIES					
1 Shareholders' funds					
(a) Share capital		615.23	615.23	615.23	615.23
(b) Reserves and surplus		4,606.22	3,957.31	3,446.22	3,298.20
(c) Money received against share warrants		0.00	0.00	0.00	0.00
Sub-total (1)		5,221.45	4,572.55	4,061.45	3,913.44
2 Share application money pending allotment		0.00	0.00	0.00	0.00
3 Non-current liabilities					
(a) Long-term borrowings		439.18	433.35	461.91	610.39
(b) Deferred tax liabilities (Net)		340.51	358.54	365.12	350.75
(c) Other Long term liabilities		0.00	0.00	0.00	0.00
(d) Long-term provisions		39.35	38.62	38.62	32.69
Sub-total (2)		819.03	830.51	865.65	993.83
4 Current liabilities					
(a) Short-term borrowings		324.79	0.00	0.00	0.00
(b) Trade payables					
Due to Micro, Small & Medium Enterprise		7.26	17.01	7.01	0.00
Due to Others		664.52	694.72	613.44	695.51
(c) Other current liabilities		246.50	498.20	269.11	200.68
(d) Short-term provisions		354.85	114.28	194.85	68.24
Sub-total (3)		1,597.92	1,324.20	1,084.42	964.43
TOTAL		7,638.41	6,727.26	6,011.52	5,871.70
II. ASSETS					
Non-current assets					
1 (a) Property, Plant and Equipment					
(i) Tangible assets		2,990.81	3,299.96	3,439.62	3,383.38
(ii) Intangible assets		0.00	0.00	0.00	0.00
(iii) Capital work-in-progress		452.23	109.47	73.90	0.00
(iv) Intangible assets under development		0.00	0.00	0.00	0.00
		3,443.03	3,409.42	3,513.52	3,383.38
(b) Non-current investments		1.00	6.65	5.65	5.65
(c) Deferred tax assets (net)		0.00	0.00	0.00	0.00
(d) Long-term loans and advances		75.82	78.07	70.50	78.74
(e) Other non-current assets		0.00	0.00	0.00	0.00
Sub-total (1)		3,519.86	3,494.14	3,589.67	3,467.78
2 Current assets					
(a) Current investments		0.00	0.00	0.00	0.00
(b) Inventories		299.67	261.05	291.68	313.35
(c) Trade receivables		1,245.14	1,461.45	1,236.84	1,242.12
(d) Cash and cash equivalents		2,116.38	1,322.25	737.92	729.97
(e) Short-term loans and advances		92.41	104.49	62.27	71.11
(f) Other current assets		364.95	83.87	93.14	47.37
Sub-total (2)		4,118.55	3,233.12	2,421.85	2,403.93
TOTAL		7,638.41	6,727.26	6,011.52	5,871.70

For and on behalf of Board of Directors
Par Drugs and Chemicals Limited

Jigneshbhai V Savani (Director & CEO)
(DIN - 00198203)
Bhavnagar, 10th June, 2021

Falgun V Savani (Managing Director)
(DIN - 00198236)
Bhavnagar, 10th June, 2021

PAR DRUGS AND CHEMICALS LIMITED

(CIN : L24117GJ1999PLC035512)

Registered Office : 815, Nilamber Triumph, Gotri Vasna Road, Vadodara (Gujarat)

Audited Financial Results for the Half Year Ended 31st March, 2021

Statement Of Profit & Loss

Rs. In Lakhs

Particulars	Half Year Ended			Year Ended	
	31.03.2021	30.09.2020	31.03.2020	31.03.2021	31.03.2020
	Audited	Unaudited	Audited	Audited	Audited
I. Revenue from operations	3,248.41	2,826.72	2,673.73	6,075.13	5,584.87
II. Other income	13.51	5.43	9.68	18.94	9.86
III. Total Revenue (I + II)	3,261.92	2,832.15	2,683.41	6,094.07	5,594.72
IV. Expenses:					
Cost of materials consumed	1,168.93	1,040.31	1,070.34	2,209.24	2,219.12
Purchases of Stock-in-Trade	0.00	0.00	0.00	0.00	0.00
Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-40.75	19.36	63.18	-21.39	146.45
Employee benefits expense	224.05	173.79	207.35	397.84	411.34
Finance costs	30.68	33.55	37.48	64.23	79.39
Depreciation and amortization expense	134.73	147.21	6.60	281.94	276.15
Other expenses	1,075.80	812.35	909.77	1,888.15	1,863.08
Total expenses (IV)	2,593.45	2,226.57	2,294.71	4,820.02	4,995.54
V. Profit before exceptional and extraordinary items and tax (III-IV)	668.47	605.58	388.70	1,274.04	599.19
VI. Exceptional items	0.00	0.00	0.00	0.00	0.00
VII. Profit before extraordinary items and tax (V - VI)	668.47	605.58	388.70	1,274.04	599.19
VIII. Extraordinary Items	-198.57	0.00	0.00	-198.57	0.00
IX. Profit before tax (VII- VIII)	867.04	605.58	388.70	1,472.61	599.19
X Tax expense:					
(1) Current tax	235.03	101.07	56.70	336.10	100.00
(2) Deferred tax	-18.03	-6.58	14.37	-24.61	22.69
XI Profit (Loss) for the period from continuing operations (VII-VIII)	650.03	511.09	317.63	1,161.12	476.50
XII Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00
XIII Tax expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00
XIV Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	0.00	0.00	0.00	0.00	0.00
XV Profit (Loss) for the period (XI + XIV)	650.03	511.09	317.63	1,161.12	476.50
XVI Earnings per equity share:					
(1) Basic.	10.57	8.31	5.16	18.87	7.75
(2) Diluted.	10.57	8.31	5.16	18.87	7.75

For and on behalf of Board of Directors
Par Drugs and Chemicals Limited

Jigneshbhai V Savani (Director & CEO)
(DIN - 00198203)
Bhavnagar, 10th June, 2021

Falgun V Savani (Managing Director)
(DIN - 00198236)
Bhavnagar, 10th June, 2021

PAR DRUGS AND CHEMICALS LIMITED
(CIN : L24117GJ1999PLC035512)
Registered Office : 815, Nilamber Triumph, Gotri Vasna Road, Vadodara (Gujarat)
Audited Financial Results for the Half Year Ended 31st March, 2021
Statement of Cash Flow

Particulars	Rs. In Lakhs			
	Half Year Ended		Year Ended	
	31.03.2021	30.09.2020	31.03.2021	31.03.2020
	Audited	Unaudited	Audited	Audited
A: CASH FLOW FROM OPERATING ACTIVITIES:				
Net profit before tax as per P & L Statement.	867.04	605.58	1,472.61	599.19
<u>Adjusted for:</u>				
Depreciation	134.73	147.21	281.94	276.15
Income-tax/Prior Year Adjustment	-1.12	0.00	-1.12	-1.04
Interest Expense	28.26	32.00	60.26	75.41
Rent, Interest & Dividend Income	-7.84	-5.43	-13.27	-7.65
Profit on Slump Sale of Ankleshar Unit	-198.57	0.00	-198.57	0.00
Profit/Loss on sale of assets	-0.03	0.00	-0.03	-2.21
	-44.57	173.78	129.21	340.66
Operating Profit /(loss) before working capital changes	822.46	779.36	1,601.82	939.85
<u>Adjustments for changes in working capital</u>				
<u>Adjustments for (increase)/decrease in operating assets</u>				
Long Term Loans & Advances	2.25	-7.57	-5.32	-1.92
Inventories	-38.62	30.63	-7.99	137.73
Trade Receivables.	216.31	-224.61	-8.31	-384.86
Short Term Loans & Advances	12.09	-42.22	-30.14	-1.23
Other Current Assets	-16.97	4.62	-12.36	-2.76
<u>Adjustments for increase/(decrease) in operating liabilities</u>				
Long-term provisions	0.72	0.00	0.72	5.93
Short-term provisions	5.54	-4.74	0.80	-1.57
Other Current Liabilities	-251.70	229.09	-22.61	35.96
Trade Payables	-39.95	91.28	51.33	127.27
	-110.34	76.47	-33.87	-85.46
Cash Generated from / (used in) Operating activities	712.13	855.83	1,567.95	854.39
Less: Income-Tax paid	-264.10	-95.35	-359.45	-85.27
Net Cash generated from / (used in) Operating Activities:	448.03	760.48	1,208.51	769.12
B: CASH FLOW FROM INVESTING ACTIVITIES:				
Purchase of Fixed Assets	-461.80	-43.11	-504.91	-155.87
Sales of Fixed Assets	492.06	0.00	492.06	2.50
Rent, Interest & Dividend Income	7.84	5.43	13.27	7.65
	43.76	-38.68	5.07	-145.72
Net Cash generated from / (used in) Investing Activities:				
C: CASH FLOW FROM FINANCING ACTIVITIES:				
Proceeds from Issue of Shares	0.00	0.00	0.00	852.72
Proceeds from Long Term Borrowings	0.00	0.00	0.00	0.00
Repayment of Long Term Borrowings	5.82	-28.56	-22.73	-141.23
Repayment of Short Term Borrowings	324.79	0.00	324.79	-431.91
Dividend Paid	-28.26	-32.00	-60.26	-75.41
Dividend Tax paid	0.00	0.00	0.00	0.00
Interest paid	0.00	0.00	0.00	0.00
	302.35	-137.46	164.89	111.46
Net Cash generated from / (used in) Financing Activities:				
Net Increase/(Decrease) in Cash and Cash Equivalents	794.13	584.34	1,378.47	734.86
Opening Balance of Cash and Cash Equivalents	1,322.25	737.92	737.92	3.06
Closing Balance of Cash and Cash Equivalents	2,116.38	1,322.25	2,116.38	737.92
Total:	794.13	584.34	1,378.47	734.86

1. Purchase of fixed assets are stated inclusive of movement of Capital Work in Progress and advance for capital goods between the commencement and end of the year and are considered as part of investing activity.

2. The cash flow statement has been prepared under the "indirect method" as set out in Accounting Standard - 3 on Cash Flow Statement issued by the Institute of Chartered Accountants of India.

For and on behalf of Board of Directors
Par Drugs and Chemicals Limited

Jigneshbhai V Savani (Director & CEO)
(DIN - 00198203)
Bhavnagar, 10th June, 2021

Falgun V Savani (Managing Director)
(DIN - 00198236)
Bhavnagar, 10th June, 2021

PAR DRUGS AND CHEMICALS LIMITED

NOTES:

1. Above audited financial results have been reviewed by audit committee in their meeting held on 10th June, 2021 and approved by the Board of Directors in their meeting held on 10th June, 2021
2. The Auditor of the company have carried out audit of the financial results for the half year and year ended 31st March, 2021 in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015 and have expressed their unmodified opinion.
3. Figures for the half year ended 31st March, 2021 are balancing figures between audited figures in respect of full financial year and the published year to date figures of the first half year. The figures up to the end of the half year ended 30th September, 2020 were subject to limited review.
4. Previous year / period figures have been regrouped / rearranged wherever necessary to make them comparable with current period figures.
5. The Company is primarily engaged in manufacturing of API, which constitute single business segment in terms of Accounting Standard 17 on Segment Reporting. Accordingly, there are no other business segments to be reported under Accounting Standard 17.
6. The Company does not have any subsidiary, associates or joint venture as on 31st March, 2021; therefore, it has prepared only standalone results as consolidation requirement is not applicable to the Company.
7. The Bank Balance is included in Cash and Cash Equivalents of the Company.
8. The above financials are available on the Company's website – www.pardrugs.com.
9. The Status of investors complaints received by the Company are as follows:
 - I. Received during the period from 1st October, 2020 to 31st March, 2021: NIL
 - II. Disposed during the period from 1st October, 2020 to 31st March, 2021: NIL
 - III. Pending as on 31st March, 2021: NIL

For and on behalf of Board of Directors

Par Drugs and Chemicals Limited

Falgun V Savani (Managing Director)

(DIN - 00198236)

**Jigneshbhai V Savani (Director
&CEO)**

(DIN - 00198203)

Bhavnagar, 10th June, 2021

To,

Date:10-06-2021

The Manager

Listing department,

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block-G,

Bandra Kurla Complex, Bandra (E),

Mumbai- 400 051

Maharashtra

Subject: Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015

Ref.: **Symbol- PAR (NSE Emerge), ISIN: INE04LG01015**

Dear Sir/Madam,


I, **Chintan P. Chauhan**, Chief Financial Officer of Par Drugs And Chemicals Limited hereby declare that the Statutory Auditors of the Company, M/s V Dhamsania & Associates, Chartered Accountants, having FRN 132499W, Partnership Firm has issued an Audit Report with unmodified opinion on Audited Standalone Financial Results of the Company for the financial year ended March 31, 2021.

This declaration is given pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016, vide Notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May 25, 2016 and Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016.

Kindly take on the record and acknowledge the receipt

Yours Faithfully

For PAR DRUGS AND CHEMICALS LIMITED


(Chintan P. Chauhan)
Chief Financial Officer




To,
The Board of Directors
Par Drugs And Chemicals Limited


CERTIFICATE OF CORRECTNESS OF FINANCIAL RESULTS

Pursuant to Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby certify that the financial results of the Company for the half year & year ended 31st March, 2021 placed before the meeting the financial results do not contain any false or misleading statement or figures and do not omit any material fact which may make the statements or figures contained therein misleading.

For Par Drugs And Chemicals Limited




(Mr. Jignesh V. Savani)
Chief Executive Officer




Date: 10/06/2021

Place: Bhavnagar

For Par Drugs And Chemicals Limited



(Mr. Chintan P. Chauhan)
Chief Financial Officer





DG PATEL & ASSOCIATES

COMPANY SECRETARIES

PROFILE OF SECRETARIAL AUDITOR

M/S D G PATEL & ASSOCIATES, Company Secretaries, was established in the year 2014 and registered with the Institute of Company Secretaries of India (ICSI) vide COP No. 13774. Mr. Dip Girishbhai Patel is proprietor of the firm and is a Fellow member of the Institute of Company Secretaries of India.

M/S D G PATEL & ASSOCIATES offers services in the area of Corporate Laws, Securities Laws, Corporate Governance matters, Due Diligence, Legal drafting of agreements etc.



Office: Opp. Bank of Baroda, Lokhand Bazar, Bhavnagar – 364001, Gujarat.

☎ 0278-2515036 +91 9898432306 ✉ csdgpatel@gmail.com